



David B. Goldstein has joined Duke University's Institute for Genome Sciences & Policy (IGSP; Durham, NC, USA). He will direct the new IGSP Center for Population Genomics and Pharmacogenetics, which IGSP director Huntington Willard sees as a new frontier in genomics. "A focus on population genomics will give us the ability to examine biodiversity, not only in humans but in other species as well, at an unprecedented level. David's recruitment will nicely complement the other IGSP centers and Duke's broader efforts in evolutionary genomics," says Willard. Since 1999, Dr. Goldstein has been the Wolfson Professor of Genetics at the Galton Laboratory at University College, London. He is the recipient of the Wolfson Research Award for his work in human genetics and genomics. In addition to his responsibilities as director, Dr. Goldstein will also serve as professor in the departments of molecular genetics and microbiology, and biology.

was vice president, global marketing for the anesthesia and critical care business unit.

ESBATEch (Zurich) has named **Thomas Loeser** as CFO and **Ulrich Feige** as director of preclinical development. Mr. Loeser previously held the position of CFO at Morphochem. Dr. Feige joins ESBATEch from his most recent position as director of pharmacology at Amgen.

Illumina (San Diego, CA, USA) has named **William H. Rastetter** as nonexecutive chairman of the board of directors and **John Stuelpnagel** as COO, a newly created position. Dr. Rastetter, an Illumina board member since 1998, will continue full time as the executive chairman of Biogen Idec. Dr. Stuelpnagel was a cofounder of Illumina, and previously served as senior vice president of operations.

Biolex (Pittsboro, NC, USA) has named **Dale A. Sander** as CFO and senior vice president, finance. He most recently served as CFO and vice president of corporate development of Maxim Pharmaceuticals.

Evotec OAI (Hamburg, Germany) has appointed **Mary C. Tanner** to the company's supervisory board. She brings 22 years of management experience from her tenure at Lehman Brothers and Bear Stearns. After her retirement from Bear Stearns, she founded Life Sciences Partners in 2004, which specializes in healthcare investment and advisory work.

Walter B. Wriston, a member of the board of directors at biotechnology companies Cygnus (Redwood City, CA, USA), ICOS (Bothell, WA, USA) and Vion Pharmaceuticals (New Haven, CT, USA) died on January 19 in New York at the age of 85. The cause was pancreatic cancer. From 1967 to 1984, Mr. Wriston was chairman and CEO of Citibank and its holding company, Citicorp. His emphasis on technological innovations, including the introduction of the automated teller machine (ATM), helped make Citibank the world's largest bank and solidified his reputation as the most influential banker of his generation. He received the Presidential Medal of Freedom, the US's highest civil honor, in June 2004. He is survived by his wife Kathy, daughter Catherine and two grandchildren.

Ranbaxy Laboratories (New Delhi, India) has appointed vice president for corporate affairs **Ramesh Adige** to the board of directors. In addition, **R. Sundar Rajan** has joined Ranbaxy from Wipro as vice president, legal.

Edward Arcuri has been named COO at Emergent BioSolutions (Gaithersburg, MD, USA), overseeing all of the company's operating functions including regulatory affairs, quality assurance, manufacturing and project management. Prior to joining the company, Dr. Arcuri served as senior vice president of manufacturing operations for MedImmune, where he was responsible for overseeing the production of FluMist.

Amicus Therapeutics (North Brunswick, NJ, USA) has announced the appointment of **John F. Crowley** as chairman and CEO. Mr. Crowley was senior vice president of Genzyme Therapeutics, and went on to become founding president and CEO of two companies, Novazyme Pharmaceuticals and most recently Orexigen Therapeutics. **Norman Hardman**, who had been serving as the CEO of Amicus, will assume the position of CSO.

Larry Ellingson has been named CEO of Protenix (Auckland, New Zealand), succeeding company founder Garth Cooper, who will serve as president and chief technical officer. Mr. Ellingson was formerly with Eli Lilly, serving in various executive positions in the global diabetes care unit. He has been involved with the American Diabetes Association as a mem-

ber of the board of directors and as chairman of national fund raising. He currently serves on the executive committee and is chairman of the board of directors. He will be based at a new Protenix office in San Diego, California.

Intercell (Vienna) has announced the appointments of **Emilio Emini** and **James R. Sulat** to the company's supervisory board. Dr. Emini is currently senior vice president and chief of vaccine development at the International AIDS Vaccine Initiative (IAVI). He joined IAVI after 20 years at Merck. From 1998 to 2003, Mr. Sulat served as CFO of Chiron. **Michael Stranz** from Kapital & Wert, an Austrian private equity fund, will leave Intercell's supervisory board.

John Lisle has been named CEO of Inpharmatica (London). Most recently, he served in the same capacity at Profile Therapeutics, and previously held a variety of commercial roles at GlaxoSmithKline and AstraZeneca. **Malcolm Weir**, Inpharmatica's outgoing chief executive, will remain on the board as CSO.



John Lisle

Transkaryotic Therapies (Cambridge, MA, USA) has announced the appointment of **Theresa Heggie** to the new position of general manager, TKT Europe. Ms. Heggie joins the company from Baxter Healthcare, where she